医药行业周报：辉瑞Mevrometostat在华启动3期临床

Investment Ratings - The report does not provide specific ratings for the chemical pharmaceuticals and traditional Chinese medicine sectors, while the biopharmaceutical sector is rated as neutral [1][3]. Core Insights - The pharmaceutical sector experienced a decline of 0.27% on October 10, 2024, underperforming the CSI 300 index by 1.33 percentage points, ranking 24th among 31 sub-industries [5]. - Among the sub-industries, pharmaceutical distribution (+0.69%) and blood products (-0.27%) performed relatively well, while vaccines (-2.68%) and medical research outsourcing (-1.51%) lagged behind [5]. - Notable stock performances included Xiangxue Pharmaceutical (+19.97%) and Hongbo Pharmaceutical (+14.24%), while Shuangcheng Pharmaceutical (-10.00%) and Baoren Medical (-9.90%) faced significant declines [5]. Industry News - Pfizer has initiated an international multi-center Phase 3 clinical study (MEVPRO-1) to evaluate the efficacy and safety of PF-06821497 in combination with enzalutamide for patients with metastatic castration-resistant prostate cancer [6]. - Mevrometostat, a targeted EZH2 inhibitor developed by Pfizer, aims to reduce cancer cell proliferation and induce cell death [6]. Company News - Heng Rui Medicine received FDA approval for its injectable paclitaxel (albumin-bound), becoming the first manufacturer to obtain this approval in the U.S. [7]. - Shapuaisi has received clinical trial approval for azithromycin eye drops from the National Medical Products Administration [7]. - Huadong Medicine's subsidiary has also received approval for clinical trials of semaglutide injection [7]. - Kanto Medical obtained a Class III medical device registration certificate for its products [7].